Researchers from the University of Warwick and Monash University have discovered a new antibiotic, pre-methylenomycin C lactone, which shows promise in combating drug-resistant bacterial infections, specifically Methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin-resistant Enterococcus (VRE). This development comes amid growing concerns over antimicrobial resistance (AMR), a significant global health threat highlighted by the World Health Organization (WHO) due to a lack of new antibiotics in development.
The discovery, detailed in the Journal of the American Chemical Society, identifies pre-methylenomycin C lactone as a potent intermediate in the natural production process of the previously known antibiotic methylenomycin A. Professor Greg Challis, a co-lead author, noted that while methylenomycin A was discovered 50 years ago, the potential of its synthetic intermediates had not been thoroughly explored for antimicrobial activity.
In laboratory tests, pre-methylenomycin C lactone demonstrated over 100 times greater antibacterial strength compared to methylenomycin A against various Gram-positive bacteria. Notably, it proved effective against the strains responsible for MRSA and VRE. The research team found no evidence of bacterial resistance to this new compound, a critical factor considering the reliance on vancomycin as a last-resort treatment.
This finding suggests a shift in antibiotic discovery strategies, encouraging researchers to explore intermediates in natural compound pathways for potential new antibiotics. Moving forward, pre-clinical testing will be necessary to further evaluate this compound’s efficacy and safety. The results thus far indicate that pre-methylenomycin C lactone may play a significant role in addressing the challenges posed by AMR, with the potential to save lives currently lost to resistant infections.